Association of Polymorphism within the Putative miRNA Target Site in the 3'UTR Region of the DRD2 Gene with Neuroticism in Patients with Substance Use Disorder

Int J Environ Res Public Health. 2022 Aug 12;19(16):9955. doi: 10.3390/ijerph19169955.

Abstract

The study aims at looking into associations between the polymorphism rs6276 that occurs in the putative miRNA target site in the 3'UTR region of the DRD2 gene in patients with substance use disorder (SUD) comorbid with a maniacal syndrome (SUD MANIA). In our study, we did not state any essential difference in DRD2 rs6276 genotype frequencies in the studied samples of SUD MANIA, SUD, and control subjects. A significant result was found for the SUD MANIA group vs. SUD vs. controls on the Neuroticism Scale of NEO FFI test, and DRD2 rs6276 (p = 0.0320) accounted for 1.7% of the variance. The G/G homozygous variants were linked with lower results on the neuroticism scale in the SUD MANIA group because G/G alleles may serve a protective role in the expression of neuroticism in patients with SUD MANIA. So far, there have been no data in the literature on the relationship between the miRSNP rs6276 region in the DRD2 gene and neuroticism (personal traits) in patients with a diagnosis of substance use disorder comorbid with the affective, maniacal type disturbances related to SUD. This is the first report on this topic.

Keywords: DRD2; SUD; addiction; dual diagnosis; gene; neuroticism; personality; rs6276.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3' Untranslated Regions / genetics
  • Humans
  • Mania
  • MicroRNAs* / genetics
  • Neuroticism
  • Polymorphism, Genetic
  • Receptors, Dopamine D2 / genetics
  • Substance-Related Disorders* / epidemiology
  • Substance-Related Disorders* / genetics
  • Substance-Related Disorders* / psychology

Substances

  • 3' Untranslated Regions
  • DRD2 protein, human
  • MicroRNAs
  • Receptors, Dopamine D2

Grants and funding

This research was funded by the National Science Center, Poland, grant number UMO-2015/19/B/NZ7/03691.